CELL & GENE CAPACITY UPDATE VIDEOS
Forge Biologics, A Member Of Ajinomoto Bio-Pharma Services, Capacity Update January 2025: Cell & Gene Therapy
See how Forge’s dedicated 200,000 sq. ft. facility, proprietary technologies, and specialized services provide expert AAV manufacturing to empower developers from discovery to delivery and every step in between.
Andelyn Biosciences Capacity Update January 2025: Cell & Gene Therapy
Here we introduce the structure and capabilities of our Laboratory Services group, a cornerstone of our commitment to excellence in pharmaceutical development.
Aldevron Capacity Update January 2025: Cell & Gene Therapy
In this session, you will discover how Alchemy technology utilizes a cell-free, enzymatic DNA manufacturing process that accelerates linDNA template production, allowing you to expedite your mRNA research and development pipeline.
Theragent Capacity Update October 2024: Cell & Gene Therapy
Our Arcadia, CA facilities provide cell therapy development, testing, manufacturing, a proprietary digital trial platform, and preclinical research through our Discovery Center.
Viralgen Capacity Update October 2024: Cell & Gene Therapy
Advance your rAAV gene therapy from concept to commercial scale, leveraging our world-leading expertise and capacity to bring life-changing treatments to patients in need.
WuXi Advanced Therapies Capacity Update October 2024: Cell & Gene Therapy
An update on our Philadelphia campus: comprehensive CGT services, from discovery to clinical production, with integrated bioanalytical testing to streamline timelines and reduce risks.
ElevateBio Capacity Update October 2024: Cell & Gene Therapy
Katie Jorgensen introduces ElevateBio BaseCamp's path to commercial readiness in cell therapy, highlighting key strategies for scaling from clinical to commercial manufacturing, with a focus on staffing, training, and preparation for 2025.
Advanced Medicine Partners Capacity Update October 2024: Cell & Gene Therapy
Gain insight into our unparalleled expertise as a leading CDMO in viral vectors, offering top-tier process development, analytical development, and manufacturing solutions.
Andelyn Biosciences Capacity Update October 2024: Cell & Gene Therapy
Discover our innovative DOE-based strategy for developing a scalable suspension platform to produce and purify AAV vectors, optimizing consistency, productivity, and quality across scales.
FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Cell & Gene Therapy
Here, we showcase our investment in cell therapy services and explore the innovative designs and expansions at the Thousand Oaks facility that will enhance GMP production capabilities.
IDT Biologika Capacity Update October 2024: Cell & Gene Therapy
With over 30 years of GMP manufacturing expertise, we offer dedicated capacity for clinical and commercial gene therapy batches, using advanced AAV platforms and proprietary cell lines.
SK pharmteco Capacity Update October 2024: Cell & Gene Therapy
Check out our enhanced capacity and expertise in supporting CGT projects, offering end-to-end solutions from viral vector and plasmid development to GMP manufacturing and regulatory support.
VintaBio Capacity Update July 2024: Cell & Gene Therapy
VintaBio has created open capacity for AAV clinical manufacturing through its streamlined VintaProcess platform which is an intensified adherent AAV process with very low impurities.
FUJIFILM Diosynth Biotechnologies Capacity Update July 2024: Cell & Gene Therapy
The capacity expansion project at our Thousand Oaks facility will add new cleanrooms, updated development labs, expanded QC labs, and high efficiency warehousing solutions.
WuXi Advanced Therapies Capacity Update July 2024: Cell & Gene Therapy
Learn how our expert and experienced team in Philadelphia supports cell therapy and viral vector production across a variety of modalities and stages of clinical and commercial manufacturing.
Alcami Capacity Update July 2024: Cell & Gene Therapy
Alcami offers method development, method validation and QC testing, as well as R&D testing support, leveraging our company’s extensive expertise in various testing platforms.
Andelyn Biosciences Capacity Update July 2024: Cell & Gene Therapy
To address the myriad of challenges that accompany AAV manufacturing, Andelyn uses a combination of reductionist and holistic approaches to perform end-to-end optimization for its platform.
Capacity Update July 2024: Cell & Gene Therapy
In addition to the immediate capacity for Draw-to-Thaw™ services in New York, NY, and Louisville, KY, we have openings for process and analytical development work in its Houston, TX facility.
Cellistic Capacity Update July 2024: Cell & Gene Therapy
Explore the latest insights and challenges in the cell therapy space, and learn how Cellistic overcomes these challenges with iPSC, focusing on regulatory strategies and cutting-edge capabilities.
ElevateBio Capacity Update July 2024: Cell & Gene Therapy
Partner with ElevateBio BaseCamp to leverage the LentiPeak™ platform for high-quality, scalable lentiviral vector production and accelerate your cell and gene therapy development.
Don't miss our next installment!
These conferences are ideal for professionals who have the authority to choose and manage CDMO relationships and need to secure capacity for their development or commercial programs.
How can we help?
Are you a supplier looking to present at our next event?